Personalized Therapies and Best Clinical Practices for Lung Cancer 2018
Overview
  • Dates of Release & Expiration: January 1, 2018 - January 1, 2019
  • Available "24/7" on-demand, to be viewed either as a CME or CE or non-accredited program
  • Expert medical oncologists
  • 8.25 Category 1 CME credits available for physicians
  • 8.25 CE credits available for nurses and pharmacists
Co-Chairs
Paul A. Bunn, Jr., MD
University of Colorado Denver
Denver, CO


Fred R. Hirsch, MD, PhD
University of Colorado Cancer Center
Denver, CO

H. Jack West, MD
Swedish Cancer Institute
Seattle, WA

 
Click here to
view this 8.25-hour webinar and earn either CME/CE credit. Requires completion of a brief evaluation form, participation in pre- and post-questions, and successfully passing a brief CME/CE test
 
Click here to
view this 8.25-hour webinar without CME or CE credit
 
 

Overview

This is an activity on the treatment and management of patients with lung cancer. The focus is on community-based medical oncology practices, but all clinicians caring for lung cancer patients are invited, including academic and research-based oncologists and allied healthcare practitioners.

The primary objective is to provide the target audience with the practical knowledge and best clinical practices to help them improve outcome in their lung cancer patients through a focus on personalized medicine with molecular and genomic testing and biomarkers, and an essential integration of the many new and emerging therapies into best practices for their lung cancer patients including immune therapy, new and novel targeted therapies, and novel uses of chemotherapy such as maintenance chemotherapy for squamous NSCLC. The target audience includes both academic and community-based lung cancer oncologists, pathologists, radiologists, surgeons, hematologists, fellows, oncology pharmacists, oncology nurses, Nurse Practitioners, physician assistants and other allied healthcare professionals. The focus is on community-based practices, but all clinicians are targeted, including academic and research-based oncologists and allied healthcare professionals.

On behalf of the world-class faculty of expert lung cancer medical oncologists, an Advanced Nurse Practitioner, and a Professor of Pharmacy, we are very pleased to invite you to attend. The activity will present practical information that is relevant to lung cancer practices, presented in case-based learning by lung cancer experts. It will provide the precise summarized information you need to be totally up-to-date on how to treat your lung cancer patients to improve their outcomes.

EDUCATIONAL STATEMENT OF NEED

In 2017, lung cancer remains the leading cause of cancer deaths in the US, and also remains a significant unmet medical need, and, is expected to be a major clinical and scientific challenge for the foreseeable future, but with modest incremental advances. According to the American Cancer Society Facts and Figures there were an estimated 225,500 new cases, and 155,870 deaths from lung cancer this in 2016, almost identical to the prior year’s data. Survival rates for patients with lung cancer vary widely depending upon the stage of the lung malignancy when it is initially diagnosed. The five-year survival rate for Stage I NSCLC is approximately 50 percent. Perhaps more importantly, because most lung cancer are diagnosed at late stages of disease, especially Stages II and mostly IV, the five-year survival rate for Stage IV NSCLC is approximately two percent. Thus, it is clear that there is incredible opportunity for improving outcomes for patients with lung cancer. What is exciting and provides optimism are the increasing advances being made with immune therapy and new-generation targeted therapies, alone and in various combinations, including chemotherapy and existing targeted therapy, and especially for NSCLC patients with the EGFR mutation, the ALK-gene rearrangement, squamous NSCLC, and patients with rare driver mutations.

Target Audience

This activity is designed to meet the educational needs of and help close the quality clinical performance practice gaps of medical oncologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Nurse Practitioners and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer and Head & Neck Cancer, including physician assistants, fellows and other HCPs. Lung cancer and Head & Neck cancer are both treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to these CME/CE activities for personalized therapies and best clinical practices.

Learning Objectives

PHYSICIANS
  1. Understand how to apply the different various approved and emerging immune therapy strategies for NSCLC patients in the treatment naïve and salvage settings.
  2. Compare and contrast the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  3. Evaluate the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  4. Analyze the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  5. Evaluate the large number of open clinical trials offering various combinations of immune and targeted therapies for NSCLC and Head & Neck cancer as possible options for enrolling eligible patients to possibly improve outcome.
  6. Compare and contrast the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  7. Understand when and how to use liquid biopsies versus larger gene panels to help guide serial biopsies when there is insufficient tissue available.
  8. Compare and contrast the various strategies targeting EGFR mutations in NSCLC, including monotherapy versus combination therapy and the impact on therapy related to differences in mutations.
  9. Evaluate the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for stage I NSCLC patients.
  10. Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  11. Compare and contrast the new FDA-approved immune therapies for squamous cell cancer of the Head & Neck (SCCHN).
NURSES
  1. Recall the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  2. List the different various approved and emerging immune therapy strategies for NSCLC patients in the treatment naïve and salvage settings.
  3. Identify the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  4. Define the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  5. List the most important open clinical trials offering various combinations of immune and targeted therapies for NSCLC and Head & Neck cancer as possible options for enrolling eligible patients to possibly improve outcome.
  6. Recall the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  7. Describe when and how to use liquid biopsies versus larger gene panels to help guide serial biopsies when there is insufficient tissue available.
  8. Recall the various strategies targeting EGFR mutations in NSCLC, including monotherapy versus combination therapy and the impact on therapy related to differences in mutations.
  9. List the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for stage I NSCLC patients.
  10. Describe the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  11. Review the new FDA-approved immune therapies for squamous cell cancer of the Head & Neck (SCCHN)
PHARMACISTS
  1. Recall the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  2. List the different various approved and emerging immune therapy strategies for NSCLC patients in the treatment naïve and salvage settings.
  3. Identify the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  4. Define the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  5. List the most important open clinical trials offering various combinations of immune and targeted therapies for NSCLC and Head & Neck cancer as possible options for enrolling eligible patients to possibly improve outcome.
  6. Recall the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  7. Describe when and how to use liquid biopsies versus larger gene panels to help guide serial biopsies when there is insufficient tissue available.
  8. Recall the various strategies targeting EGFR mutations in NSCLC, including monotherapy versus combination therapy and the impact on therapy related to differences in mutations.
  9. List the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for stage I NSCLC patients.
  10. Describe the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  11. Review the new FDA-approved immune therapies for squamous cell cancer of the Head & Neck (SCCHN)

Faculty & Disclosures

Paul Bunn, Jr., MD (Co-Chair)
Distinguished Professor
James Dudley Chair in Lung Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Denver, CO

Consulting Fees: : AstraZeneca, Bristol-Myers Squibb, Genentech, Novartis, Lilly, Pfizer
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Associate Professor,
Department of Hematology/Oncology
Lung Cancer and Mesothelioma TRDG Member,
Fox Chase Cancer Center
Philadelphia, PA

Salary: Fox Chase Cancer Center
Consulting Fees: Bristol-Myers Squibb, Lilly, Novartis, AstraZeneca, Merck, EMD-Serono, Celgene, Pfizer, Boehringer-Ingelheim, Genentech, Genmab
Other (Please describe): Clinical trial support: Millennium, Celgene/Merck
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Walter J. Curran, Jr., MD
Executive Director,
Winship Cancer Institute
Associate Vice President,
Cancer,Woodruff Health Sciences Center
Lawrence W. Davis Professor and Chairman of Radiation Oncology
Group Chairman and Principal Investigator, NRG,
Atlanta, GA

Consulting Fees: AstraZeneca, Bristol-Myers Squibb
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Marianne Davies, DNP, ACNP, AOCNP
Oncology Nurse Practitioner-Thoracic
Smilow Cancer Center at Yale New Haven,
Yale Comprehensive Cancer Center
Assistant Professor Yale School of Nursing,
West Haven, CT

Fees for non-CME/CE Services Received Directly from Commercial Interest or Their Agents (e.g. speakers’ bureaus): Genentech, BMS, AstraZeneca, Merck

Fred R. Hirsch, MD, PhD (Co-Chair)
Professor of Medicine and Pathology
Pia and Fred R. Hirsch Endowed Chair
Associate Director,
University of Colorado Cancer Center
CEO, International Association for the Study of Lung Cancer (IASLC)
Denver, CO

Consulting Fees: Genentech, BMS, Lilly, Merck, AstraZeneca

Jim M. Koeller, MS
Professor University of Texas at Austin
College of Pharmacy Pharmacotherapy Division
Adjoint Professor,
University of Texas Health Science Center at San Antonio
School of Medicine Pharmacotherapy Education & Research Center
University of Texas Health Science Center at San Antonio,
San Antonio, TX

Consulting Fees: Teva, Array, Cumberland
Fees for non-CME/CE Services Received Directly from Commercial Interest or Their Agents (e.g. speakers’ bureaus): Lilly, Pfizer, Merck, Takeda, Eisai
Contracted Research: Tesaro

Ronald B. Natale, MD
Director of the Lung Cancer Clinical Research Program,
Samuel Oschin Comprehensive Cancer Institute,
edars-Sinai Medical Center,
Los Angeles, CA

Contracted Research: AstraZeneca, Genentech/Roche, Merck, Peregrine
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Suresh Ramalingam, MD
Professor of Hematology/Oncology, Deputy Director
Winship Cancer Institute, Director,
Lung Cancer Program
Winship Cancer Institute,
Assistant Dean for Cancer Research
Co-Leader,
Discovery & Developmental, Therapeutics Program
Emory University, Atlanta, GA

Consulting Fees: Amgen, AbbVie, Bristol-Myers Squibb, Celgene, Novartis, Boehringer-Ingelheim, Merck, AstraZeneca

Greg Riely, MD
Medical Oncologist,
Thoracic Oncology Service,
Vice Chair, Clinical Trials Office
Department of Medicine,
Memorial Sloan-Kettering Cancer Center
New York, NY

Contracted Research: Pfizer, Novartis, Takeda
Other (Please describe): Travel expenses: Merck

Heather A. Wakelee, MD
Associate Professor,
Department of Medicine,
Division of Oncology
Member,
Stanford Cancer Institute,
Stanford Clinical Cancer Center
Stanford, CA

Consulting Fees: Peregrine, ACEA, Pfizer, Helsinn, Genentech (uncompensated)
Contracted Research: Clovis, Exelixis, AstraZeneca, MedImmune, Genentech/Roche, Bristol-Myers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Lilly
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Deborah A. Wong, MD, PhD
Professor, Oncology,
Ronald Reagan UCLA Medical Center
UCLA Medical Center,
Santa Monica, CA

Consulting Fees: Bristol-Myers Squibb

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA

Consulting Fees: Ariad, AZ, B-I, BMS, Celgene, Genentech/Roche, Guardant, Merck, Novartis, Pfizer, Trovagene
Fees for non-CME/CE Services Received Directly from Commercial Interest or Their Agents (e.g. speakers’ bureaus): Ariad, Genentech/Roche, Lilly
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

BioMedical Learning Institute

LEAD NURSE PLANNER
Diane D. DePew, DSN, RN-BC
I have no real or apparent conflicts of interest to report.

PLANNER & CME/CE REVIEWER
Stephen G. Madison, BSPharm, MBA, CHCP (BMLI Manager)
I have no real or apparent conflicts of interest to report.

CME/CE PEER REVIEWER
Danielle Shafer, MD
I have no real or apparent conflicts of interest to report.

Peer Review Process of Conflicts of Interest

This educational activity has been independently peer-reviewed.

Disclosure of Unlabeled Uses

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians' Desk Reference.

The Biomedical Learning Institute (BMLI) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the BMLI. Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.

CME/CE Accreditation & Credit Designation

To receive CME/CE credit participation in the entire activity by viewing the activity and the completion of a brief evaluation form, participation in pre- and post-questions, and successfully passing a CME/CE test.

The Biomedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Biomedical Learning Institute designates this enduring activity for a maximum of 8.25 AMA PRA Category 1 Credits™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.


The Biomedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-17-003-H01-P
Credits: 8.25 hours (0.825 ceus)
Type of Activity: Knowledge

The Biomedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's COA.

The Biomedical Learning Institute designates this educational activity for 8.25 contact hours.

Accreditation by the American Nurses Credentialing Center's COA refers to recognition of educational activities and does not imply approval or endorsement of any product.

Participation at the entire activity, a 70% or better score on the post-test and completion of the evaluation form is required to receive CE contact hour credit.

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 8.25 hours of Category 1 credit for attending this activity.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

Educational Support

Sincere appreciation is extended to Bristol-Myers Squibb, Celgene, AstraZeneca, Takeda Oncology, Lilly, and Novartis for their generous support of this educational activity

Endorsed as an Educational Activity by

Global Resource for Advancing Cancer Education (GRACE)

Click here for the Computer System Requirements to view this webinar